Stockscreener 앱 받기
1.90
2.06%
-0.04
시간 외 거래:
1.94
0.04
+2.11%
전일 마감가:
$1.94
열려 있는:
$1.95
하루 거래량:
5.04M
Relative Volume:
0.51
시가총액:
$655.79M
수익:
$22,000
순이익/손실:
$-173.76M
주가수익비율:
-2.4736
EPS:
-0.7681
순현금흐름:
$-109.53M
1주 성능:
+4.40%
1개월 성능:
-5.00%
6개월 성능:
+23.38%
1년 성능:
+38.69%
1일 변동 폭
$1.90
$1.97
1주일 범위
$1.75
$2.10
52주 변동 폭
$0.9842
$4.46
Allogene Therapeutics Inc Stock (ALLO) Company Profile
명칭
Allogene Therapeutics Inc
전화
(650) 457-2700
주소
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.90 | 669.60M | 22,000 | -173.76M | -109.53M | -0.7681 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2026-04-10 | 재개 | Jefferies | Buy |
| 2026-01-09 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-05-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | 재개 | Oppenheimer | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-08-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-28 | 재확인 | B. Riley Securities | Buy |
| 2021-10-20 | 개시 | Cowen | Outperform |
| 2021-10-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | 재개 | Jefferies | Buy |
| 2021-05-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-14 | 개시 | B. Riley Securities | Buy |
| 2021-01-26 | 업그레이드 | Stifel | Hold → Buy |
| 2020-12-10 | 재개 | H.C. Wainwright | Buy |
| 2020-11-24 | 개시 | BofA Securities | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-06-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-19 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2020-05-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-14 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-04-13 | 개시 | SunTrust | Buy |
| 2020-03-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-24 | 개시 | Berenberg | Hold |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-05 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Neutral |
| 2019-05-23 | 개시 | Stifel | Hold |
| 2019-03-29 | 개시 | Piper Jaffray | Overweight |
모두보기
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Why is Allogene Therapeutics (ALLO) down 12.2% since last earnings report? - MSN
ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’ - Stocktwits
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report? - Yahoo Finance
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Gilead Sciences, Kite Pharma, Novartis, BMS, Allogene Therapeut - Barchart.com
Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio - Insider Monkey
A pioneering founder is stepping down as CEO of his Bay Area company ahead of a major test - The Business Journals
CMO Roberts to succeed Chang as Allogene CEO - BioCentury
Certain Restricted Stock Units of Allogene Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
Certain Common Stock of Allogene Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
Allogene Therapeutics Names Zachary Roberts as New CEO - The Globe and Mail
Allogene Therapeutics, Inc. 8-K SEC Filing May 28, 2026: Company Details, Common Stock, and Exchange Information - Minichart
Allogene CEO to step down; Agios drug fails key test - BioPharma Dive
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Allogene Therapeutics (ALLO) Announces Leadership Transition - GuruFocus
Allogene Therapeutics names Zachary Roberts CEO in planned succession - MSN
Allogene Therapeutics names Zachary Roberts as new CEO By Investing.com - Investing.com South Africa
Allogene Therapeutics CEO David Chang Steps Down - marketscreener.com
Allogene Therapeutics announces planned CEO succession - marketscreener.com
Allogene Therapeutics names Zachary Roberts as new CEO - Investing.com
Zachary Roberts named Allogene President and CEO, David Chang stepping down - TradingView
Allogene Therapeutics (ALLO) elevates Zachary Roberts to CEO with major equity awards - Stock Titan
Allogene Therapeutics, Inc. Announces CEO Changes - marketscreener.com
Allogene Therapeutics (ALLO) Surges 6%: Can the Biotech Reclaim Key Resistance?On Balance Volume - thelegaladvocate.com
ALLO Stock Steadies As Cash Runway Extends To 2029 On Trial Progress - StocksToTrade
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - The Manila Times
Cancer cell therapy firm Allogene lines up three investor talks - Stock Titan
ALLO News | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill
Allogene Therapeutics posts narrower-than-expected loss in Q1 - MSN
Allogene Therapeutics explores ALPHA3 trial potential for allogeneic CAR T in LBCL treatment - Traders Union
JPMorgan, Allogene Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
Earnings call transcript: Allogene Therapeutics Q1 2026 sees mixed results with revenue miss By Investing.com - Investing.com South Africa
Earnings call transcript: Allogene Therapeutics Q1 2026 sees mixed results with revenue miss - Investing.com UK
ALLO Technical Analysis | Trend, Signals & Chart Patterns | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill
Number of shareholders of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Allogene outlines cash runway into Q1 2029 while raising 2026 operating cash expense guidance to ~$165M - MSN
Allogene Therapeutics unveils ALLO-329 with Dagger technology for next generation cell therapy - Traders Union
Citadel affiliates, Kenneth Griffin report stakes in Allogene (ALLO) - Stock Titan
Lynx1 amends 13G for Allogene Therapeutics (NASDAQ: ALLO) showing 0% stake - Stock Titan
Allogene Therapeutics | SCHEDULE 13G/A: Others - Moomoo
A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $7 to $14 - Moomoo
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2026 Earnings Call Transcript - Insider Monkey
Piper Sandler Sticks to Their Buy Rating for Allogene Therapeutics (ALLO) - The Globe and Mail
Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO) - The Globe and Mail
Analysts’ Top Healthcare Picks: Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN) - The Globe and Mail
A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $9 to $14 - Moomoo
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 7.7%Here's What Happened - MarketBeat
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1 - The Globe and Mail
Oppenheimer Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Allogene Therapeutics Inc (ALLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):